3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
8
Sarcoma
7
Sarcoma, Clear Cell
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Neoplasm Metastasis
2
Liposarcoma
2
Kidney Neoplasms
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Glioblastoma
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Solid Neoplasm
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Refractory or Recurrent Solid Tumor
1
Perivascular Epithelioid Cell Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Adipose Tissue
1
Myoepithelioma
1
Liposarcoma, Myxoid
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
pazopanib
×
1 year
×
Clear all
No trials found.